BioCentury
ARTICLE | Clinical News

Magainin starts Phase II in ovarian cancer

February 3, 2000 8:00 AM UTC

MAGN began U.S. Phase II trials of its squalamine angiogenesis inhibitor in patients with ovarian cancer. The studies will examine squalamine in combination with carboplatin in recurrent ovarian cance...